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DOSE THRESHOLD FOR CLINICAL SUCCESS IN CORONARY BRACHYTHERAPY:

A

NESTED CASE-CONTROL STUDY. Harsimran S. Singh, Ning Yue, Nassir Azimi, Kenneth B.
Roberts, Ravinder Nath, and Steven Pfau. Section of Cardiovascular Medicine, Department of
Internal Medicine, Yale University, School of Medicine, New Haven, CT
Intravascular brachytherapy is the primary treatment for coronary in-stent restenosis. We
hypothesized that differences in dose delivered to target may contribute to treatment failures. We
compared dose distribution between arteries that developed recurrent restenosis (treatment failures)
and those that remained patent at nine-months (treatment success). A cohort of 207 patients receiving
brachytherapy for coronary in-stent restenosis with four radiation delivery devices was followed to
identify treatment failures and successes. This cohort was examined to establish which patient and
lesion characteristics had an effect on outcome. A nested case-control construct was then used in
which treatment failures (n=14) were compared 1:2 to treatment successes (n=28) matched by two
variables: radiation delivery system and angiographic pattern of in-stent restenosis. At baseline, the
groups had similar patient and lesion characteristics. The dose absorbed by 90% of the artery
encompassed by the external elastic membrane (D90EEM) was calculated using intravascular
ultrasound (IVUS) images taken at 2-mm intervals along the treated lesion. Dose calculations were
performed using dose kernel integration techniques; the dose kernels were generated from Monte
Carlo simulations. The mean D90EEM minimum dose in treatment failures was 7.46±1.98 Gy, while
for treatment success the mean D90EEM minimum dose was significantly higher: 8.87±1.13 Gy
(p=0.007). Using a dose threshold of 8.4 Gy, a D90EEM minimum dose < 8.4 Gy occurred in 13
(93%) patients with treatment failure, but in only 9 (32%) with treatment success (p<0.001). No
confounding variables were found to be statistically significant. In conclusion, current brachytherapy
dose prescriptions result in significant inter- and intra-lesion variation in dose at the EEM. Arteries
that receive < 8.4 Gy at any point along the EEM are more likely to be treatment failures. IVUS
guided dosimetry may be critical to assure adequate dose regardless of radiation delivery system.
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5
INTRODUCTION

Angioplasty is a standard non-surgical treatment of ischemia due to vascular stenosis
most often caused by atherosclerosis. A major limitation of angioplasty has been restenosis
(diameter renarrowing of ≥50% on angiographic follow-up) of the treated vessel. It can occur
acutely or subacutely in 30 to 50% of coronary angioplasty cases – generally within the first ~3
months post-balloon dilation (1). The causes of restenosis after balloon angioplasty include
neointimal hyperplasia, elastic vascular recoil, arterial dissection, thrombosis formation, and
atherosclerotic remodeling (1,2).
For the past decade and a half, coronary interventions have included the placement of
intravascular stents in addition to balloon angioplasty. From amongst the ~900,000 angioplasties,
performed annually in the USA, ~70-80% include coronary stent placement. Stenting has been
established to reduce angiographic and clinical restenosis when compared to percutaneous
balloon interventions alone – by virtually eliminating the problem of elastic recoil and
remodeling (3,4). However, restenosis after stenting continues to persist – 15-35% of patients
develop restenosis of the affected site within the first 6-8 months after stent placement (3,5-7),
with clinically driven repeat coronary revascularization necessary in 50-80% of those cases. (7-9).
Given the prevalence of stenting/angioplasties and thus the overall disease burden of restenosis, a
large amount of research has been invested over the past two decades in attempting to discern its
pathophysiology and find ways to prevent and appropriately treat the problem.

In-Stent Restenosis
In-stent restenosis (ISR) is secondary to neointimal hyperplasia – an endovascular
infiltration of inflammatory cells, fibroblasts, and myo-fibroblasts in response to the injury
induced by angioplasty and stenting. Unlike the chronic pathology leading to atheroma
formation, ISR may be localized or distributed over the length of the stent and is likely due
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to a maladaptive response to vascular injury (10). The neointimal proliferation occurs in
conjunction with macrophage and myo-fibroblast recruitment, presumably found within
the tunica intima and also migrating from the tunica adventitia (11).
Several patient and lesion characteristics have been documented in the literature to affect
ISR rates including: diabetes (12), long lesion length (13), small artery diameter (13), acute
coronary syndrome (14), renal failure (12), and saphenous vein bypass grafts (15). Patterns of
restenosis have been described by Mehran et al that encompasses lesion length as well as the
relationship of tissue proliferation to the implanted stent. In-stent lesions are classified via an
ordinal rank of Types I through IV – ranging from focal lesions of restenosis to total stent
occlusion. This system captures the magnitude of the proliferative response and is shown to
predict long term prognosis (16).
While ISR and specifically neo-intimal hyperplasia is a problem over the first 6-8 months
post stenting, there may be no further regression in luminal diameter or clinical failure at one-year
and beyond (17,18). The problem of ISR has been tackled through a variety of tactics in the past,
including repeat angioplasties, ablative devices, laser ablation, and rotational artherectomy – all
with minimal success in affecting recurrence rates and clinical course.

Radiation Therapy Theorized
The idea of radiation therapy for treating ISR in the vasculature was adapted from other
fields of medicine relying upon radiation. For many years this modality has been used to inhibit
growth of tumor cells and non-malignant hyperplasias (post-surgical keloids, heterotrophic bone
formations, recurrent pterygium, etc). Brachytherapy literally means “local treatment” using
radiation (as opposed to external beam radiation), thus limiting systemic side effects of diffuse
radiation exposure. Given our present day understanding of the pathology behind atherosclerosis,
intravascular brachytherapy (IVBT) was theorized to be of benefit by preventing endothelial/
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intimal hyperplasia and/or matrix deposition after balloon injury – by either mediating apoptosis
or inhibiting cellular proliferation (19).
Over the past decade, two classes of ionizing radiation have been investigated – 1)
Gamma rays (low energy/high penetration) using 192-Ir and 2) Beta-particles (high energy/low
penetration) using a variety of isotopes including 32-P, 90-Sr/90-Y, 188-Re, and 133-Xe. The
radiation can be delivered either via a catheter-based system (ribbon, fixed-length wire, seed
trains, and balloons – for radioisotopes in liquid phase) allowing temporary exposure or stentbased system for permanent implantation. Radiation may be delivered over a course ranging
from 3 to 30 minutes depending on the dose required and isotope used.

Brachytherapy: Clinical Trials
Initial proof-of-concept and dosing for IVBT was established through animal studies after
which it was attempted in humans. The first large scale randomized control trial for IVBT was
SCRIPPS – a double blind trial (n=55) for in-stent restenosis and de-novo restenosis – showed a
70% reduction of restenosis rates (53.6% v. 16.7% by angiography) with IVBT v. placebo at 6
months; and a continuation of the effect at 3 years – 66.6% v. 33% restenosis. The SCRIPPS trial
recently published a five-year follow-up of their patients – in which the clinical effectiveness of
IVBT is shown to slightly diminish over time, but maintains improved clinical outcomes. This
positive result led to a series of multi-center trials each supporting one of the three IVBT systems
currently in use. 1) GAMMA-1 (20,21) was the premier multi-center double blind randomized
control trial (n=252) for in-stent restenosis trailed the Cordis - Checkmate system (192-Ir). This
study found a 36% reduction in major adverse cardiac events (MACE) in IVBT v. placebo
(28.2% v. 43.8%). 2) START (22) was a significant multi-center trial that examined 472 patients
in determining efficacy/safety of the Novoste - BetaCath balloon system (90-Sr/Y) for in-stent
restenosis. They found 9-month revascularization rates to be 24% placebo v 16% Beta-VBT. 3)
INHIBIT (23) further solidified Beta-IVBT’s efficacy and safety. Examining 332 patients using
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32-P source (Guidant – Galileo) with 20 Gy dose 1 mm into vessel wall, INHIBIT found a 66%
reduction in restenosis rates at 9 months. The clinical and angiographic outcomes found in these
three trials are presented in Figures 1 & 2. Given the positive results of these studies, in
November 2000, two systems for delivery of coronary IVBT were approved by the Food & Drug
Administration (FDA): the BetaCath system by Novoste and the Checkmate System by Cordis
(24). A third system, Galileo by Guidant, was approved one-year later in November 2001
(23,25).

Brachytherapy Success & Reality
Over the past three years, brachytherapy has become established as the frontline
treatment option for in-stent restenosis. While drug-eluting stents may prove to be viable
alternatives for ISR in the future, IVBT has remained the only consistently proven treatment for
ISR with decreased rates of repeat revascularization (26). As described above, three large multiinstitutional, randomized control trials documented a 30-50% improvement in outcome compared
to angioplasty alone, primarily driven by reduction in angiographic restenosis and the need for
repeat revascularization (20-23).
To date very little data has emerged regarding the clinical application of IVBT in patients
who receive treatment for ISR outside of clinical trials. The RENO registry provided multiinstitutional outcomes on the use of the Novoste BetaCath system in Europe, providing insight
into the more generalized application of this device. At 6-month follow-up, the rate of MACE in
RENO was 18.7%, similar to the randomized control trial. RENO helps to prove that the clinical
benefit of brachytherapy can be maintained outside of the strict environment of trial design
(27,28), but there were two caveats to this study. First, the registry was limited to patients treated
with the Novoste radiation system. Second, the analysis included patients with de novo lesions,
which comprised 20% of the study population. To date there has been no study examining all
three approved brachytherapy systems in a general population.
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Despite this initial success, brachytherapy has not been the unconditional panacea for
ISR. Depending on the trial, 15 to 29% of patients given IVBT will still fail treatment and
require another revascularization procedure within 9-months (20,29,30). Certain risk factors
associated with increased IVBT failure include diabetes (31,32), renal failure (33), and saphenous
vein grafts (SVG) (34). There also have been inverse associations with age (35), lesion length
(36), and minimal luminal diameter (MLD) (36).
Two complications related to brachytherapy treatment are edge restenosis and an
increased risk for late thrombosis. Edge restenosis occurs when an inadequate dose is given to
the edge of the stent, due to either dose fall out with inadequate dose prescriptions or due to
“geographic misses” – where portion of the injured vessel are not accounted for when planning
treatment. This problem can be counteracted by adequate coverage (37). Late thrombosis was a
problem in initial studies, especially in patients who received additional stenting in addition to
IVBT – however with long-term anti-thrombosis therapy this problem has been diminished
(38,39).

Brachytherapy Dosing
One factor that may be related to brachytherapy outcomes is radiation dose. Few studies
have explored the effects of ionizing radiation dose-distribution within the artery and different
types of radiation sources (among the 3 FDA IVBT approved systems – different isotopes, Beta
v. gamma sources) to clinical outcomes. Animal data has suggested that doses between 8 and 40
Gray (Gy) are effective (40-45), but steep dose gradients and concerns regarding toxicity have
pushed clinical prescriptions to the lower limit of this range. Early clinical studies used
ultrasound to prescribe at least 8 Gy to the external elastic membrane (EEM), but adjusted dose to
avoid more than 30 Gy to the nearest part of the vessel (20,21).
At present, radiation prescriptions for IVBT are rather empiric. Dose (in Gray as a
measure of absorbed energy in tissue per unit mass) is prescribed either at a fixed amount at a
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standard depth (generally at 2 mm depth from a radiation line source) or to a histological target
such as the EEM (radiolucent border on ultrasound). A minimal dose to the EEM in turn insures
a minimal dose distribution to the intima, thought to be one putative biologic target in IVBT.
While the exact cellular target for IVBT remains uncertain, in vitro data suggests that cells from
the adventitia, media and neointima may all be involved (19,43,46). Current strategies have
focused on delivering enough radiation to the entire vessel wall without exceeding vessel
tolerance. As radiation dose from a line source decreases rapidly as a function of distance from
that source, the vessel wall is exposed to a highly variable dose gradient – with additional
variability between different isotopes and dose prescriptions (Figure 3). Dosing remains
imprecise as the vascular anatomy and the position of the radiation source within the lumen are
variable.
Current day dose prescriptions have evolved towards dosing regimens that are based on
very few patient or lesion specific criteria. All three FDA-approved brachytherapy devices
recommend dose prescriptions which are standardized to a fixed distance from the source, with
small adjustments based on lumen size for the beta emitters. However, parameters such as plaque
burden, plaque distribution (concentric v eccentric), vessel curvature, and catheter position all
contribute to uneven dose distribution because they affect the variability in distance from the
source to EEM (47,48). These factors result in variations of dose to target, which may ultimately
impact the efficacy of this therapy.
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STATEMENT OF PURPOSE & HYPOTHESIS

Over the past few years, brachytherapy has been clinically established to be a frontline
treatment option for in-stent restenosis. Several multi-institutional, double blind randomized
control trials have been conducted with 6 months to 5 years follow-up, all touting the
effectiveness of IVBT for preventing MACE, repeat intervention, and site specific restenosis (as
per angiography). However, there is minimal literature regarding the brachytherapy experience
outside of clinical trials. Also, few studies have explored the role of radiation dose-distribution
within the artery and its potential effect on the treatment efficacy of brachytherapy. The goal of
this study is two fold:

1) Determine clinical effectiveness of brachytherapy at our institution & examine patient/lesion
characteristics that may affect outcomes.
Yale New Haven Hospital’s Endovascular Brachytherapy Center has been performing
IVBT since November 2000 – and subsequently has a wealth of retrospective data that has not
been formally explored. In this study, we reviewed our single-center experience with intracoronary IVBT of 207 patients between November 2000 and November 2002 with subsequent 9month clinical outcomes. We examined these patients’ clinical data, including their specific
IVBT regimen and angiographic/ultrasound parameters with their clinical outcomes within the
first 8-9 months post-IVBT. By examining this cohort of patients, we hope to establish
preliminary associations that assist in formulating parameters for dose prescription/distribution
and radiation source selection for IVBT.
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2) Examine the relationship between de facto dose distribution and brachytherapy treatment
success.
Given the variation in vascular anatomy, plaque distribution & burden, catheter
placement, and brachytherapy systems/isotopes used, we hypothesize that despite standardized
dose prescriptions, patients are in reality receiving very different amounts of radiation, and this
variability may lead to treatment failure. We used a nested case-control construct using
intravascular ultrasound (IVUS) images to examine dose delivered to the EEM in patients across
radiation devices who failed brachytherapy treatment compared to those who had a durable result.
Treatment failures (n=14) were compared 1:2 to treatment successes (n=28) matched by two
variables: radiation delivery system and angiographic pattern of in-stent restenosis. Our findings
could lead to a refinement of dosing protocols and ultimately improvement in brachytherapy’s
treatment of ISR.
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METHODS

A. Treatment Cohort Methodology
Cohort Study Population
We retrospectively examined the patient cohort who underwent intravascular
brachytherapy at Yale New Haven Hospital between November 2000 and November 2002 – a
total of 216 patients and 245 lesions. Brachytherapy was performed on all referred patients with
clinical evidence of ischemia and ISR evident by cardiac catherization, aside from two patients
for whom IVBT was aborted because of technical difficulties in radiation catheter placement.
IVBT was administered by one of four devices: 1) Novoste - BetaCath system – Beta radiation
using 90-Sr/Y; 2) Cordis - Checkmate – Gamma radiation using 192-Ir; and 3) Guidant - Galileo
– Beta radiation using 32-P. 4) Interventional Therapy – Gamma radiation using 192-Ir as part of
clinical trial. None of the patients in our study had received intravascular brachytherapy prior to
this treatment. This study was approved by the Yale Human Investigation Committee in
accordance with institutional guidelines.

Intervention and Brachytherapy Protocol
Diagnostic catheterization was performed separate from the intervention in the majority
of cases. This allowed for decisions regarding appropriateness for brachytherapy, treatment
planning and, device selection, especially early in the series when source length was a limiting
factor in some cases. Anticoagulation was achieved using unfractionated heparin to achieve a
target activated clotting time (ACT) of 300 seconds. Glycoprotein 2b/3a inhibitors were used
only as a bailout strategy. All cases were completed with 8F-guiding catheters. Coronary
intervention was performed using cutting balloon, rotational atherectomy, or balloon angioplasty.
After the best angiographic result was obtained, IVUS was performed in all cases. If further
intervention was indicated from ultrasound imaging, another IVUS run was performed
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immediately prior to brachytherapy treatment. Lumen dimensions for the purposes of
brachytherapy dose prescriptions were taken from MLD as designated by IVUS in all cases.
Several factors were used to determine the device for radiation delivery. Many patients
in the first 6 months of the series were enrolled in research studies, which dictated device
selection. Early in the series, the Checkmate device was used for the longest lesions, as the
BetaCath was limited to a 40mm source (30mm injury length), and we avoided manual
“stepping” of shorter sources because of inherent inaccuracies in delivered dose (49). Beta
emitters were favored if patients became ischemic during the intervention or if it was the clinical
impression of the operator that long dwell time would not be tolerated. Using this strategy, no
cases required fractionation of treatment. Gamma sources were favored in arteries with heavy
calcification, or where significant length of overlapping stents (>2-3mm) was present. In
addition, we favored gamma sources for treatment of vein graft lesions because of the relative
absence of data for beta-emitters in this anatomic subset. All patients were encouraged to
continue dual antiplatelet therapy for at least six months. If a new stent was placed at the time of
the brachytherapy procedure, we recommended 12 months of antiplatelet therapy.

Collection of Data & Analysis
This study was approved by the Yale Human Investigation Committee.

We compiled a

database including information from a) the patient’s medical records – cardiac/medical histories,
risk factors, comorbidities; b) angiography images – lesion and injury length, vessel
diameter/degree of occlusion; c) IVUS images – MLD, dose-distribution within the vessels;
d) Radiation treatment records – source type and dose prescription. Double entry of data was
done to ensure accuracy.
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Coronary angiograms were reviewed by two independent observers who classified lesions
as per the ISR classification system described by Mehran et al (16):
Class I: Focal ISR group. Lesions are 10 mm in length and are positioned at the
unscaffolded segment (i.e., articulation or gap), the body of the stent, the proximal or
distal margin (but not both), or a combination of these sites (multifocal ISR)
Class II: "Diffuse intrastent" ISR. Lesions are >10 mm in length and are confined to the
stent(s), without extending outside the margins of the stent(s).
Class III: "Diffuse proliferative" ISR. Lesions are >10 mm in length and extend beyond
the margin(s) of the stent(s).
Class IV: ISR with "total occlusion." Lesions have flow grade of 0.

Patient Follow-up/Outcomes
Clinical outcomes were obtained for patients at 9 months by telephone contact with the
patients and confirmed by their referring/primary physicians. As a quality control mechanism,
the Yale Endovascular Brachytherapy Center uses a pre-established, standardized questionnaire
to ask patients about their health status since undergoing brachytherapy – including whether or
not they had stress testing, coronary artery bypass grafting (CABG), repeat percutaneous
transluminal coronary angioplasty (PTCA), myocardial infarction (MI), and/or regular follow-up
with a physician. This database was utilized as the major source of endpoint identification. From
the 216 patients (245 lesions) treated with IVBT between November 2000 and November 2002,
nine were lost to follow-up, leaving 207 patients (236 lesions) available for analysis– 96%
follow-up. Patients lost to follow-up were double checked in the National Death Index to
minimize selection bias. All cardiovascular endpoints were confirmed through the patients’
referring cardiologists and/or primary care physicians.
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B. Case-Control Methodology
Nested Case-Control Patient Selection
In order to perform detailed dosimetry, patients with reported MACE (that includes
death, PTCA, CABG, and myocardial infarction) were identified from the Yale Endovascular
Brachytherapy database who had received brachytherapy between November 2000 and June
2002. Follow-up angiography was reviewed to confirm treatment failure. Cases were eligible for
inclusion as treatment failures if the target lesion treated was within a native coronary artery, and
failure of the target lesion was confirmed by angiography as the cause of MACE. Cases with
documented geographic miss were excluded (50).
Patients in our cohort who did not report MACE at 9 months were eligible as treatment
successes. Treatment successes (controls) were then matched 2:1 to failure cases by two
variables: 1) radiation delivery system and 2) angiographic pattern of ISR, according to the
classification devised by Mehran et al (16).

IVUS Contours & Analysis
Images from the pre-radiation IVUS acquisition were printed every 2 mm throughout the
lesion length (Figure 4). These images were scanned into an in-house computer calculation
system and scaled to reflect their actual dimensions. Contours demarcating the EEM of the
coronary vessel were drawn on each scanned image.
Figure 5 displays a typical EEM drawn on one of IVUS slices. The accuracy of this
contouring was verified by two cardiologists. All steps of the dose distribution analysis were
blinded to patient outcomes.
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Dosimetry Calculations
The catheter-based radioactive source was assumed to be a line source with the
radionuclide used in the treatment uniformly distributed over the length of the source and with the
same length and strength as that used in the treatment. Dosimetric calculations were performed
using a numerical integration method. Assuming that the point dose rate kernel per unit source

v

v

strength of the radionuclide in interest is k (r ) , the dose at a point of r is then (51):

v
v v
v
v
D (r ) = ∫ k ( r − r ′) ρ (r ′)Td r ′
L

Where L is the length of radioactive source used in the treatment, ρ(r) is the source strength per
unit length at the point r in the source, and T is the treatment time. The point dose rate kernels of
various radionucliotides were obtained with Monte Carlo simulation in water. The doses were
normalized to the prescription doses at the prescription points. The accuracy of the dose
calculation was verified by the point-dose calculations at various points (other than the
prescription points), comparing to the dose values provided by the manufacturers. It was
assumed that the source was positioned where the IVUS catheter was located in the slice-based
IVUS images, except for treatment catheters with a centering balloon in which case the source
was assumed to be centered within the lumen. The longitudinal location of the source relative to
IVUS slices was determined by comparing the IVUS images and corresponding angiograms.
Dose surface histogram (DSH) was calculated on the EEM for each examined slice
(Figure 5) (52). The DSH was computed as follows: on each slice of interest, the EEM was
divided into numerous points 0.001 mm apart from each other. The dose calculations were then
performed on all the points. The calculated doses and percent of the points (representing EEM)
were tabulated to form DSH. It should be noted that the dose calculations performed for DSH
were only done on the contoured EEM lines, not on any points inside or outside the lines. Figure
5 shows a typical integral DSH. From the DSH on each slice of interest, the minimal dose that
encompassed 90% of the EEM (D90EEM) was determined. This is analogous to a parameter that
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is predictive of success with cancer brachytherapy. Subsequently, the minimum, maximum, and
average D90EEM, were derived along the treated lesion.

C. Statistical Analysis
A composite outcome measure commonly referred to as MACE was utilized. Continuous
data is presented as means with standard deviations, and discrete variables are presented as
frequencies. Post-brachytherapy outcomes and bivariate analyses were described by KaplanMeier analysis, Pearson’s Chi Square, and Independent T-test as required. Multivariate analysis
was performed by conditional logistic regression to account for the controls matched to two
variables. The multivariate model was restricted to four covariates to account for study size.
SPSS 11.5 software was used to carry out statistical calculations.

D. Delineation of Work
As with most good research, our study was the joint effort of a group of dedicated
individuals. The actual brachytherapy procedure was administered by a team consisting of Dr.
Steven Pfau, Dr. Kenneth Roberts, and Dr. Ning Yue. The study concept was conceptualized by
Dr. Steven Pfau, Dr. Kenneth Roberts, and Dr. Ning Yue. The epidemiological construct and
study methodology was designed by Dr. Steven Pfau and Harsimran Singh. The dosimetry
calculations described above were theorized and carried forth by Dr. Ravi Nath and Dr. Ning
Yue. The IVUS delineation and angiography review (lesion typing) was performed by Harsimran
Singh, Dr. Nassir Azimi, and Dr. Steven Pfau. The brachytherapy database (data collection) was
made by Harsimran Singh. Cohort outcomes were obtained by Harsimran Singh, Mike Cabin,
and Carol Roberts. Data analysis, statistical work, and team coordination was performed by
Harsimran Singh. Data interpretation was performed by Harsimran Singh and Dr. Steven Pfau.
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RESULTS

A. Patient Cohort Results
Patient demographics& Angiographic Characteristic:
Table 1 outlines the clinical characteristics of our study population. From amongst 207
patients, 152 (73%) were males whose ages ranged between 35-86 with a mean age of 63 and a
corresponding 55 (27%) females with age range of 43-86 with a mean age of 67. The most
prevalent clinical presentation that resulted in IVBT referral was unstable angina with 154 (74%).
From the cohort, 149 (72%) had diagnosed hypertension, 152 (73%) hyperlipidemia, 66 (32%)
diabetes (Type I and Type II), and 23 (5%) chronic renal insufficiency (defined by a baseline
creatinine of > 1.5). Also, 82 (40%) patients had a previous myocardial infarction and 57 (27%)
had undergone prior CABG.

Table 1. Cohort Characteristics & Outcomes (207 patients)
Pt Characteristics
Male
Average Age (years)

152 (73.4%)
62.5 ± 12.6

Clinical Presentation
Unstable Angina
Stable Angina
Positive Stress Testing
Post-MI
Other

154 (74.4%)
23 (11.1%)
14 (6.8%)
12 (5.8%)
4 (1.9%)

Risk Factor Profile
Hyperlipidemia
Hypertension
Diabetes – Types 1 & 2
Chronic Renal Insufficiency
(Baseline Creatinine >1.5)
Smoking
Cardiac Family History
(1st degree relative)
Past Cardiac History
Remote MI
CABG

152 (73.4%)
149 (72.0%)
66 (31.9%)
23 (11.1%)
39 (18.8%)
87 (42.1%)
82 (39.6%)
57 (27.5%)
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Angiographic Characteristics
A total of 236 coronary lesions in 207 patients were treated with IVBT as listed in Table
2: the left anterior descending (LAD) in 78 (33%) lesions, circumflex (CFX) in 45 (19%) lesions,
right coronary (RCA) in 73 (33%) lesions, ramus in 5 (2%) lesions, SVG in 33 (14%) lesions, and
left internal mammary artery (LIMA) in 2 (1%). A total of 177 (75%) lesions were treated with
cutting balloon or a combination of cutting balloon and standard balloon, and 48 (20%) lesions
required additional stenting. The mean injury length for IVBT treatment was 22 mm.
Table 2: Vessel / Lesion Characteristics (n=236)
Variable

# of patients (%)

Vessel
LAD
CFX
RCA
SVG
Ramus
LIMA

78 (33.1%)
45 (19.1%)
73 (30.9%)
33 (14.0%)
5 (2.1%)
2 (0.8%)

Average Injury Length (mm)
Average MLD - post PTCA (mm)

22.44 ± 10.28
3.07 ± 0.49

Primary PTCA Modality
Cutting Balloon
Rotational Atherectomy
Balloon Only
Additional Stenting

177 (75.0%)
17 (7.2%)
38 (16.1%)
48 (20.3%)

Radiation Treatment
The Novoste BetaCath device
was the most frequently used device,
comprising 69% of cases (Table 3).
This stems in large part from the fact
that it was the first clinically available
device, and was obtained by the Center

in April of 2001. The Galileo device was available at Yale only as an investigational device
during the period of this cohort, explaining the low number of patients treated with this device.
Radiation dosing schemes were used as approved by the FDA for each individual system. Also
outlined in Table III are the mean dose prescriptions for each brachytherapy system. Two
patients had minimally shortened radiation treatment times due to ischemia (94% and 96% of
prescription), while one patient had an increased treatment time (101% of prescription), due to
difficulty in removing the radiation seeds.
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Table 3: Brachytherapy System Used
Radiation System

Seed Train
Length

Dose Prescription

Lesions Treated

30
30

23 Gy @ 2mm from source
18.4 Gy @ 2mm from
source
23 Gy @ 2mm from source
18.4 Gy @ 2mm from
source
23 Gy @ 2mm from source
18.4 Gy @ 2mm from
source

34
42

39
39
55
55

14 Gy @ 2mm from source
8 Gy at furthest EEM
14 Gy@ 2mm from source
8 Gy at furthest EEM

8
12
8
28
----56

45

18 Gy @ 2 mm from
source

13

60

20 Gy @ 1 mm into artery
wall

4

Novoste (Beta – 90-Sr/Y)

40
40
60
60
Cordis Checkmate (Gamma – 192Ir)

Interventional Therapy (Gamma –
192-Ir)

38
43
4
2
----163

Guidant Galileo (32-P)

Outcomes In-Hospital
There were no in-hospital deaths. Four lesions developed significant dissections during
PTCA, all of which were treated successfully by additional stenting prior to IVBT. Two lesions
were unable to be completely encompassed by IVBT due to tapering of the target vessel lumen
diameter distal to the lesion. The IVUS catheter could not be passed into four lesions; in these
cases MLDs were estimated from angiography alone. Two patients had enzymatic evidence of
non-Q-wave myocardial infarction after the procedure. One patient with severe LV dysfunction
and a large territory at risk had prophylactic placement of an intra-aortic balloon pump prior to
the procedure. None of the patients required CABG surgery or emergent PTCA during their
initial hospitalization. There was no incidence of subacute stent thrombosis.
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Outcomes at 9-Month Follow-up
Table 4 summarizes the clinical outcomes obtained for our patient cohort at a mean time
9.1 months (± 2.8 months). 44 patients (21%) experienced MACE through our follow-up.
Table 4: Clinical Outcomes at 9 months
(n=207)
Outcome Measure

# of patients (%)

MACE
Repeat PTCA
CABG
MI
Death

44 (21.3%)
21 (10.1%)
19 (9.2%)
3 (1.4%)
1 (0.5%)

No MACE

163 (78.7%)

The large majority of MACE was in patients
requiring repeat revascularization (91%), evenly
divided between PTCA and CABG. One patient
with severe LV dysfunction died during the
follow-up period. The one-year outcomes for
our study population are illustrated in Figure 6

by means of a Kaplan Meier Survival Curve. Upon bivariate analysis of lesion and patient
characteristics with outcomes (Tables 5 & 6), age (p=0.001), PTCA modality (0.037), and vessel
type (p=0.002) were found to have a statistically significant effect upon outcome. An established
diagnosis of hypercholesterolemia may eventually show a statistically significant effect on 9month MACE with augmentation of the sample size (currently p= 0.156). Upon performing
stepwise logistic regression with each independent variable, only age maintained statistical
significance (p=0.001).

Table 5: Bivariate Analysis of Lesion Characteristics
Variable

MACE (n= 31)

No MACE (n=109)

Age

58.24 ± 9.46

64.75 ± 12.88

Statistical PValue
0.001

Mean Lesion Length

23.40 ± 10.28

22.16 ±10.29

0.445

Mean MLD

3.07 ± 0.54

3.07 ± 0.48

0.990
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Table 6: Bivariate Analysis of Patient/Lesion Characteristics
Variable

Variable Choices

Number of
Patients

8-month
freedom from
event (%)

Statistical P-value

Male
Female

152
55

77.0
83.6

0.301

≥65
<65

98
109

87.8
70.6

0.001

Yes
No

149
58

77.9
81.0

0.615

Yes
No

152
55

76.3
85.5

0.156

Yes
No

66
141

75.8
80.1

0.472

> 1.5
≤ 1.5

23
184

70.0
79.9

0.254

Yes
No

57
150

79.3
77.2

0.737

Yes
No

82
125

81.7
76.8

0.399

Cutting
Balloon
Rotational
Atherectomy

177
17
38

79.1
76.3
58.8

0.037

Yes
No

48
188

73.7
76.1

0.650

78
45
73
33
5
2

75.6
62.2
89.0
78.8
60.0
0.0

0.002

Gender

Age

Hypertension

Hypercholesterolemia

Diabetes

Creatinine

Previous CABG

Previous MI

Type of Treatment
Angioplasty

Additional Stenting

Vessel
LAD
CFX
RCA
SVG
Ramus
LIMA
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Section B. Case-Control Results

For the case-control segment of this study, only patients treated with brachytherapy
between November 2000 and June 2002 were eligible. During this period, 145 patients (161

lesions) were treated for in-stent restenosis. The baseline characteristics of this cohort are
reiterated in Table 7, and are consistent with those of the larger cohort described in
Results Section A. During this period, five patients were lost to follow-up, leaving 140
patients available for analysis. At 9 months, 31 patients had reached significant MACE:
16 (11%) patients required repeat PTCA, and 14 (10%) patients needed CABG. Two
patients were reported having an MI, and there was one death (Table 7).

Table 7. Cohort Characteristics & Outcomes
(140 patients | 156 lesions)
Pt Characteristics
Male
Average Age (years)
Clinical Presentation
Unstable Angina
Stable Angina
Positive Stress Testing
Post-MI
Other
Risk Factor Profile
Hyperlipidemia
Hypertension
Diabetes –
Type II
Type I
Chronic Renal Insufficiency
(Baseline Creatinine >1.5)
Smoking
Cardiac Family History
(1st degree relative)
Past Cardiac History
Remote MI
CABG
Clinical Outcomes (at 9-months)
MACE
Repeat PTCA
CABG
MI
Death
No MACE

102 (73%)
64 (35-86 range)
112 (80%)
10 (7%)
10 (7%)
6 (4%)
2 (1%)
100 (71%)
96 (69%)
36 (26%)
7 (5%)
11 (8%)
25 (18%)
58 (41%)
55 (39%)
34 (24%)
31 (22%)
16 (11%)
14 (10%)
2 (1%)
1 (1%)
109 (78%)
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Case-Control Patient Selection & Characteristics
All 31 clinical failures were reviewed for use in the dosimetry analysis. Four patients
were excluded because the treatment segment was either a saphenous vein or internal mammary
artery graft. Five patients were excluded because the point of failure was outside the treated
segment. Two patients were excluded because of geographic miss. Of the remaining 20 patients,
6 were excluded from analysis because the EEM was not adequately visualized (at least 270
degrees identifiable in at least 90% of the IVUS images); this was most commonly related to
shadowing from calcification or severe non-uniform rotational distortion. This left 14 patients
with in-field failures of native coronary arteries with adequate IVUS imaging available for
analysis (Figure 7).
Table 8. Variables Used to Match
Controls with Cases
Brachytherapy System
Novoste
(Beta – 90-Sr/Y)
Cordis Checkmate
(Gamma – 192-Ir)
Interventional Therapy
(Gamma – 192-Ir)
Guidant Galileo
(Beta – 32-P)
Beta Radiation
Gamma Radiation
Lesion TypeA
Type I
Type II
Type III
Type IV
Types I & II
Types III & IV

Controls were then selected
from the 109 patients who remained

Cases (n=14)

Controls (n=28)

4

10

8

15

1

3

failures in a 2:1 ratio; radiation

1

0

delivery system and angiographic

5
9

10
18

pattern of in-stent restenosis were the

MACE-free at 9-months. All controls
were native coronaries matched to

variables used to match cases to
3
5
6
0

7
11
7
3

8
6

18
10

controls (Table 8).
Matching created 2 groups that
were similar with regard to

demographics, lesion length, final MLD (by IVUS), and PTCA treatment modality (Table 9).
Chronic renal failure and diabetes were slightly more common in the controls than in the cases,
and more additional stenting was performed in the control group compared to failures.
A

Lesion typing system as designated by Mehran: Circulation, 100(18): 1872-187.
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Table 9. Patient & Lesion Characteristics of Cases & Controls

Patient Characteristics
Male
Average Age (years)
Clinical Presentation
Unstable Angina
Stable Angina
Positive Stress Testing
Post-MI
Risk Factor Profile
Hyperlipidemia
Hypertension
Diabetes – Types I & II
Chronic Renal Insufficiency
(Baseline Creatinine >1.5)
Smoking
Cardiac Family History
(1st degree relative)
Past Cardiac History
Remote MI
CABG
Treated Vessel
LAD
CFX
RCA
Lesion Dimensions
Average Injury Length (mm)
Average MLD post-PTCA (mm)
Primary PTCA Modality
Cutting Balloon
Rotational Atherectomy
Balloon Only
Additional Stenting

Cases (n=14)

Controls (n=28)

12 (86%)
60.00 ± 8.98

22 (79%)
60.39 ± 12.88

13 (93%)
0 (0%)
0 (0%)
1 (7%)

19 (68%)
1 (4%)
4 (14%)
4 (14%)

11 (86%)
11 (79%)
3 (21%)
0 (0%)

20 (71%)
22 (79%)
9 (32%)
1 (4%)

3 (21%)
8 (57%)

7 (25%)
15 (54%)

2 (14%)
3 (21%)

16 (57%)
1 (4%)

5 (36%)
5 (36%)
4 (28%)

12 (43%)
5 (18%)
11 (39%)

29.21 ± 11.73
2.82 ± 0.43

26.71 ± 10.83
2.89 ± 0.63

12 (86%)
1 (7%)
1 (7%)
3 (21%)

23 (82%)
2 (7%)
3 (11%)
9 (32%)

Dose Distribution v. Clinical Outcomes
For every study patient, the D90EEM was calculated for each IVUS slice along the entire
length of radiation treatment, inclusive of the entire injury length. D90EEM were then compiled to
extrapolate the minimum, maximum, and average D90EEMs for each lesion. An average of 22
slices was analyzed per lesion. A longitudinal display of D90EEM for one lesion is illustrated
below (Figure 8).

27
Figure 9 illustrates the minimum D90EEMs plotted for all 42 patients. The mean
minimum D90EEM for the cases was 7.46 ± 2.07 Gy, while for the controls it was 8.87 ± 1.13 Gy.
Upon bivariate analysis, minimum D90EEM was found to be a statistically significant predictor of
clinical success (p=0.007). All other patient and lesion characteristics were analyzed by bivariate
analysis (selected variables shown in Table 10):

Table 10. Bivariate Analysis of Selected Variables
Including Dose Distribution & Outcomes
Cases (n=14)

Controls (n=28)

P-Value

Age (yrs)
Diabetes
Hyperlipidemia
Remote MI
Remote CABG
Lesion Length (mm)
MLD (mm)
Primary PTCA Modality
Cutting Balloon
Rotational Atherectomy
Balloon Only

60.00 ± 8.98
3 (21%)
11 (86%)
2 (14%)
3 (21%)
29.21 ± 11.73
2.82 ± 0.43

60.39 ± 12.88
9 (32%)
20 (71%)
16 (57%)
1 (4%)
26.71 ± 10.84
2.89 ± 0.63

0.919
0.469
0.306
0.008
0.063
0.496
0.393

12 (86%)
1 (7%)
1 (7%)

23 (82%)
2 (7%)
3 (11%)

0.933

Average D90EEM Dose (Gy)
Maximum D90EEM Dose (Gy)
Minimum D90EEM Dose (Gy)

10.50 ± 3.06
13.62 ± 5.97
7.46 ± 2.07

10.90 ± 1.70
14.24 ± 2.86
8.87 ± 1.13

0.586
0.681
0.007

Minimum D90EEM Dose ≤ 8.4 Gy
Minimum D90EEM Dose > 8.4 Gy

13 (93%)
1 (7.1%)

7 (33%)
14 (67%)

<0.001

Only the presence of remote MI was found to be statistically significant (p=0.008). The
maximum and average D90EEM were neither numerically nor statistically different between the
groups (figures not shown).
Using the dose distribution data displayed (Figure 9), a threshold for minimum dose of
8.4 Gy demarcates clinical success from failure reasonably well. Using this threshold, 13 (93%)
of the cases had a minimum D90EEM ≤ 8.4 Gy, while only 7 (33%) of the controls were below
this minimum (p<0.001). A multivariate model was used including dose threshold, age, diabetes,
remote MI, and lesion length. Minimum D90EEM ≤ 8.4 Gy remained a significant predictor of
clinical outcome with an odds ratio of 0.022 (CI of 0.002 to 0.300) when compared to minimum
D90EEM > 8.4 Gy. No other variable examined in our multivariate model was significant. Step-
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wise, logistic regressions were also performed examining every variable in the multivariate
analysis (Table 11). Only minimum D90EEM retained its statistical significance.

Table 11. Logistical Regression Model of Select Variables for Clinical Success

Minimum D90EEM Dose
≤ 8.4 Gy
> 8.4 Gy
Age
< 65
≥ 65
Diabetes
Yes
No
Remote MI
Yes
No
Lesion Length
< 25 mm
≥ 25 mm

A

OR indicates odds ratios.

Odds Ratio

Lower 95% Limit ORA

Upper 95% Limit OR

0.022
1.000

0.002
1.000

0.300
1.000

0.371
1.000

0.054
1.000

2.555
1.000

1.000
0.315

1.000
0.041

1.000
2.402

1.000
0.194

1.000
0.025

1.000
1.518

1.000
0.603

1.000
0.082

1.000
4.447
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DISCUSSION

Cohort Analysis Documenting Brachytherapy’s Effectiveness:
We present our single-institution experience with coronary brachytherapy over the first
two years since FDA approval in November of 2000. When applied to a broad group of patients
with ISR, using a variety of delivery devices, intracoronary brachytherapy is safe and effective.
Our 9-month MACE rate of 21.3% corresponds well with clinical outcomes reported in the
radiation groups of the three hallmark randomized control trials: GAMMA-1 (28% at 9-months)
(20,21), START (18% at 6-months) (22), and INHIBIT (22% at 6-months) (23). All patients
were treated with prolonged dual anti-platelet therapy, and there were no instances of late stent
thrombosis. While the larger Novoste based RENO registry in Europe has been reported (27,53),
our registry is unique in that it incorporates experience with all the currently available devices
and is limited strictly to patients treated for in-stent restenosis.
Several important lessons can be learned from the transition from initial clinical trials to a
more general experience. First, when patients generally excluded from clinical trials are
examined, there is no significant change in overall outcome. In our series, patients with SVG
(14%) lesions, multivessel treatments (14%), total occlusions (9%) and chronic renal failure
(11%), would have been excluded from randomized trials. Still, our cohort maintained treatment
efficacy in spite of 36% of the total being “high risk” patients. Second, universal treatment with
dual antiplatelet therapy resulted in elimination of the clinical entity of late thrombosis that was
seen in earlier clinical trials (39,54,55). Without complete angiographic follow-up, however, the
incidence of “subacute” late thrombosis (i.e. clinically silent total occlusion of the target vessel)
could not be excluded. Finally, other procedural parameters that have been related to worse
outcomes in prior studies, such as additional stenting at the time of brachytherapy (27), had no
effect on outcome in our series (see table 5).
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In bivariate and multivariate analysis of continuous variables, age was found to be a
statistically significant inverse predictor of outcome. This finding is consistent with observations
made by Ajani (35), as well as in the RENO registry (27). The reasons for the improved outcome
in the elderly are not entirely clear; one hypothesis suggests that the ability for cellular
regeneration and proliferate response to injury diminishes with age (35). Lesion length and
smaller MLD were not related to clinically driven revascularization, although other studies have
suggested that these factors are important in target vessel restenosis (36). Bivariate analysis of
dichotomous variables failed to uncover any other significant relationships to outcome, similar to
other studies of both diabetes (31,32), and chronic renal insufficiency (33). Use of cutting
balloon was associated with better outcome, similar to the findings of the RENO registry in
addition to several other studies (56-58). It has been suggested that precise limitation of injury
with the cutting balloon may improve IVBT results by reducing the likelihood of geographic
miss.
Certain limitations inherent in observational research must be considered when
interpreting our findings. While clinical endpoints are the most important effect of any therapy,
we were unable to precisely differentiate between target lesion failure, target vessel failure, and
non-target vessel failure in many cases because of lack of complete angiographic reexamination.
Nevertheless, there is a paucity of published data about IVBT in a non-controlled case mix, and
even less information derived from a ‘real world’ utilization of all three available IVBT devices.
Yale Endovascular Brachytherapy Center’s philosophy of using all available devices is a
unique feature of this cohort. Early in the series device selection was primarily dictated by lesion
length, but in several instances we allowed treatment with a secondary device when the initial
device could not be negotiated into the target lesion. Furthermore, we believe strongly that
appropriate device selection prevented severe ischemia during treatment and any need for dose
fractionation. Ultimately this philosophy of device selection based on lesion characteristics will
result in improved clinical outcomes, however too many of the patients in this particular cohort
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had the device dictated by availability of source train length. Our more recent experience is that
all devices now have the ability to treat injury lengths of 50mm, and the lesion characteristics that
affect isotope-specific dose delivery such as calcium, overlapping stents, vessel curvature,
involvement of bifurcations, and saphenous vein graft target will dictate device selection in order
to most completely deliver dose to target.
The recent entry of drug-eluting stents into the US market will hopefully reduce the
overall incidence of in-stent restenosis. At present, brachytherapy is the treatment of choice for
ISR because it is proven, effective, and safe. Ongoing randomized trials of drug-eluting stents for
restenosis may provide alternatives for this patient population, and ultimately the relative
utilization of these modalities will be driven by efficacy, ease of application, and economics.
Experiences from trials of IVBT have driven changes in practice that have further refined the
protocol for IVBT treatment, leading to improved short-term and long term outcomes. Technical
improvements in catheter design and familiarity with the use of this modality have improved its
penetration into the overall interventional practice. Based on this data as well as that from other
broad registries, it is likely that brachytherapy will remain an important part of the interventional
landscape for the foreseeable future.

Case Control Suggesting a Dose Threshold for Clinical Success:
The second goal of this study was to explore the possibility of dose distribution playing a
role in dictating clinical success. To our knowledge, this is the first study of coronary
brachytherapy examining the relationship between actual delivered dose and clinical outcomes in
a cohort of patients treated with a variety of radiation delivery devices, isotopes, and dose
prescription algorithms. We used a standardized method to assess dose delivery across radiation
devices in order to establish the relationship between delivered dose and outcome after IVBT.
This study is also the first to suggest that there is a relationship between delivered dose and
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revascularization rates in coronary brachytherapy for in-stent restenosis regardless of device used
to deliver that dose.
Other investigators have examined the relationship between dose and outcome, but those
studies have differed in two important ways. First, all have focused on a single delivery device
and isotope. Second, these studies have primarily examined the relationship between dose and
intimal tissue volume as assessed by IVUS (59-62). Although intimal tissue volume can be a
surrogate for clinical outcomes in most of these prior studies the need for repeat revascularization
was low, suggesting that changes in intimal tissue volume were not an appropriate correlate for
the clinical effectiveness of coronary brachytherapy. Verin et al did show a relationship between
angiographic restenosis and dose prescription using an Sr90 source (63). In de novo lesions
treated with balloon angioplasty alone, dose prescriptions were 9, 12, 15, or 18Gy that resulted in
angiographic restenosis rates of 29, 21, 16 and 15 percent. This translated into an improvement
in clinical outcome, with a revascularization rate of 18% in the lowest dose group and 6% in the
highest dose group. Unfortunately, this study did not include an IVUS examination, so that the
relationship was between outcome and dose prescription rather than delivered dose. Furthermore,
this study was of de novo lesions rather than in-stent restenosis.
A series of studies from Waksman’s group have addressed the issues of dose with gamma
emitters. In an IVUS based analysis of long, diffuse ISR treated with brachytherapy, both volume
of intimal hyperplasia and minimum lumen area at follow-up were related to target distances (64).
Although specific dosimetric analysis was not performed, a fixed dose prescription (15 Gy at
2mm) was used, so that longer source to target distances would have resulted in lower dose to the
EEM. In a comparison of two dose prescriptions (15 or 18 Gy at 2mm), Waksman and
colleagues showed that by IVUS parameters (60) or by angiographic restenosis and MACE (65),
higher dose prescriptions were associated with better outcomes.
The optimal dose and target for brachytherapy for in stent restenosis was not rigorously
examined in the pivotal clinical trials. Animal data suggests a dose-response in intimal growth
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after balloon over-stretch injury in porcine coronary arteries, with the lowest doses (3.5 Gy)
resulting in increased intimal growth, but higher doses (up to 14 Gy) showed a progressively
beneficial effect (43,66). In the first series of patient treatments, dose prescriptions were as high
as 25Gy at a distance of 1.5mm from the Ir192 source (67). Due to the lack of centering, estimates
for maximum dose delivered to the vessel surface were as high as 92.5Gy. Concern for toxicity
to the vessel at these doses led to the use of IVUS based prescription algorithms to limit “near
field” doses to 30 Gy in the earliest randomized trials of gamma emitters (20,68). Randomized
trials of beta emitters (23,69) did not use IVUS guided dosimetry, and have not performed IVUS
analysis of delivered dose. For these isotopes (Sr90 and P32) steeper dose gradients would result in
high lumen doses relative to Ir192. None of the current dose prescription algorithms take into
account source to target distance, i.e. the variability of distance to the EEM from the lumen.
Our finding that a dose threshold of 8.4 Gy at the EEM exists is the first time that such a
high dose has been associated with clinical success. In the SCRIPPS trial, angiographic late loss
was significantly decreased when the adventitial border received at least 8 Gy (62). Because of
small numbers, however, this paper was not able to relate dose to clinical failure. Further, it is
important to note that this threshold exists across devices in our study. Although in other diseases
there may be some difference in biologic effect related to dose rate of a specific isotope, these
differences may not be as important in the coronaries (70).
The study is limited because of relatively small numbers and its retrospective design.
Furthermore, the patients were not consecutive, but selected primarily based on the
interpretability of the IVUS images. Other important determinants of dose delivery, such as
degree of vascular calcification, curvature, and degree of stent overlap were not included as
variables in this analysis. We limited our analysis to patients who suffer “in-field” failure, which
does not account for all patients who require target vessel revascularization after coronary
brachytherapy. Another limitation of the current study is the assumption that the line source
location was assumed to be synonymous with the IVUS catheter.
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In early studies, intravascular brachytherapy focused on dose in an effort to balance
concerns of toxicity with proof of efficacy. These studies, both in animals and patients, suggested
a dose response, and the concern for vascular toxicity led to IVUS guided dose prescriptions in
the first randomized clinical trials primarily to avoid excessive “near field” doses. IVBT has
resulted in remarkably consistent improvement in outcomes regardless of isotope, and dose
prescriptions are standardized using only visual estimates of lumen diameter for dose adjustment.
Abandoning routine IVUS improves short term time and cost efficiencies in the catheterization
laboratory, but at a great loss of artery specific information that is important to clinical outcome.
The data in our study argues that we should not settle for dose algorithms that are ‘sufficient’ to
allow a 20-40% failure rate; rather further refinement of our dosing strategy is necessary. The
improved image quality and general availability of IVUS, as well as future developments in
intravascular imaging, should push this field to refine dose prescription to maximize benefit while
minimizing potential toxicity. We believe that this study adds to the body of existing evidence
that shows how improved outcomes in coronary brachytherapy are related to dose. Vessel and
plaque anatomic data obtained by IVUS should be used in all patients undergoing brachytherapy
to determine an optimal dose prescription.
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ABBREVIATIONS

IVBT

=

intravascular brachytherapy

ISR

=

in-stent restenosis

EEM

=

external elastic membrane

IVUS

=

intravascular ultrasound

CABG

=

coronary arterial bypass grafting

PTCA

=

percutaneous transluminal coronary angioplasty

MI

=

myocardial infarction

MACE

=

major adverse cardiac events

FDA

=

Food & Drug Administration

DSH

=

dose surface histogram

ACT

=

activated clotting time

LV

=

left ventricular

MLD

=

minimal luminal diameter

D90EEM

=

minimal dose that encompasses 90% of the
external elastic membrane
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FIGURES

Figure 1. Clinical Outcomes of Brachytherapy Trials: This chart compares the percentage of major
adverse cardiac events (MACE) between placebo and brachytherapy groups of three multi-center
randomized control trials.A
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Figure 2. Angiographic Outcomes of Brachytherapy Trials: This chart compares the percentage of
target vessel revascularization (TVR) between placebo and brachytherapy groups of three multicenter randomized control trials.A
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Figure 3. This figure illustrates theoretical dose variation for several different dose prescriptions and
isotopes. It shows the de facto dose delivered is highly variable upon the distance to the target site.
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Figure 1. IVUS Segments Across Target Vessel: Caricture shows basic premise of obtaining 2mm
IVUS images across the span of the irradiated lesion.
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Figure 2. Sample IVUS with Dose Histogram: The external elastic membrane (EEM) outlined on a
typical IVUS slice and its corresponding dose surface histogram (DSH).
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Figure 3. Kaplan-Meier survival curve over one year of the study cohort.
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Figure 4. Schematic of Case-Control: Details the inclusion and exclusion criteria used to select
patients eligible for case-control study.
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Figure 5. Dosing for a Single Vessel: A longitudinal display of the dose absorbed by 90% of the
artery encompassed by the external elastic membrane (D90EEM) in intravascular ultrasound IVUS
slices every 2 mm across a treated lesion. The maximum, mi
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Figure 6. Dose Threshold: Distribution of the minimum dose absorbed by 90% of the artery
encompassed by the external elastic membrane (D90EEM) for each study patient. Triangles
represent cases (treatment failures). Diamonds represent the matched co

